Table. Patient Characteristicsa.
| Characteristic | Overall (N = 226) | Intervention arm | ||
|---|---|---|---|---|
| True acupuncture (n = 110) | Sham acupuncture (n = 59) | Waiting list control (n = 57) | ||
| Age, median (range), y | 60.7 (27.0-80.6) | 60.7 (34.1-80.6) | 57.0 (40.5-77.5) | 60.6 (27.0-76.0) |
| Hispanic | ||||
| Yes | 21 (9.7) | 11 (10.0) | 7 (12.1) | 3 (5.3) |
| No | 204 (90.3) | 99 (90.0) | 51 (87.9) | 54 (94.7) |
| Unknown | 1 | 0 | 1 | 0 |
| Race | ||||
| Asian | 15 (6.8) | 11 (10.4) | 2 (3.4) | 2 (3.6) |
| Black | 10 (4.5) | 6 (5.7) | 2 (3.4) | 2 (3.6) |
| American Indian | 1 (0.5) | 1 (0.9) | 0 | 0 |
| Pacific Islander | 1 (0.5) | 0 | 0 | 1 (1.8) |
| White | 193 (87.7) | 88 (83.0) | 54 (93.1) | 51 (91.1) |
| Unknown | 6 | 4 | 1 | 1 |
| Breast cancer stage | ||||
| I | 97 (43.7) | 41 (38.7) | 28 (47.5) | 28 (49.1) |
| II | 99 (44.6) | 53 (50.0) | 23 (39.0) | 23 (40.4) |
| III | 26 (11.7) | 12 (11.3) | 8 (13.6) | 6 (10.5) |
| Unknown | 4 | 4 | 0 | 0 |
| Prior chemotherapy | 111 (49.1) | 56 (50.9) | 31 (52.5) | 24 (42.1) |
| Prior tamoxifen | 43 (19.0) | 18 (16.4) | 15 (25.4) | 10 (17.5) |
| Current or prior AI therapyb | ||||
| Anastrozole | 164 (72.6) | 80 (72.7) | 44 (74.6) | 40 (70.2) |
| Letrozole | 70 (31.0) | 36 (32.7) | 17 (28.8) | 17 (29.8) |
| Exemestane | 41 (18.1) | 21 (19.1) | 10 (16.9) | 10 (17.5) |
| Time receiving AI therapy, median (range), y | 1.1 (0.1-9.0) | 1.0 (0.1-8.0) | 1.1 (0.1-9.0) | 1.1 (0.1-3.1) |
| Prior acupuncture | 44 (19.5) | 19 (17.3) | 13 (22.0) | 12 (21.1) |
Abbreviation: AI, aromatase inhibitor.
a
Data are presented as number (percentage) of patients unless otherwise indicated. Percentages are calculated among those with known data.
b
Number answering yes (>1 type allowed).